Inovio Pharmaceuticals Announces $16 Million Public Offering of Common Stock and Warrants

On April 2, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler & Co. for a public offering of 12,500,000 shares of common stock. Each share is being sold at a combined public offering price of $1.40 alongside two types of warrants: one Series A warrant (exercisable for one year) and one Series B warrant (exercisable for five years), both with an exercise price of $1.40. Investors may also opt for pre-funded warrants in lieu of common stock or warrants to manage beneficial ownership limits. The company granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares and corresponding warrants. Inovio expects to receive net proceeds of approximately $16 million from the offering, after deducting discounts and estimated expenses, assuming no exercise of the over-allotment option. The offering is conducted under an existing shelf registration statement and is expected to close around April 6, 2026. The funds are intended for general corporate purposes.